CAMP

CAMP4 Therapeutics Corporation is a biopharmaceutical company developing medicines that modulate gene regulatory networks to treat genetic diseases. Headquartered in Cambridge, Massachusetts, CAMP4 focuses on a novel therapeutic approach targeting regulatory RNAs that control gene expression patterns. The company's platform technology involves identifying and modulating non-coding RNAs that serve as master regulators of disease-associated genes, with the goal of restoring healthy gene expression levels. CAMP4 is developing therapies for diseases including pulmonary conditions, neurodevelopmental disorders, and other genetic diseases where restoring proper gene regulation may provide clinical benefit. The company's approach differs from traditional gene therapy by aiming to optimize endogenous gene expression rather than introducing new genetic material. CAMP4 utilizes advanced genomics, computational biology, and machine learning to map gene regulatory networks and identify therapeutic targets. The company has raised capital from specialized life science investors and maintains research collaborations with academic institutions. CAMP4 is advancing multiple programs through preclinical and clinical development stages. The company's scientific team includes experts in RNA biology, genomics, and drug development working to translate regulatory RNA insights into targeted therapies for patients with serious genetic diseases.